StreetInsider.com News Articles

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Tue, 07 Jul 2026 08:00:00 -0400

BOSTON & MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline.

Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Tue, 07 Jul 2026 08:00:00 -0400

Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Tue, 07 Jul 2026 08:00:00 -0400

Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Tue, 07 Jul 2026 08:00:00 -0400

Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Tue, 07 Jul 2026 08:00:00 -0400

Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Tue, 07 Jul 2026 08:00:00 -0400

Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Tue, 07 Jul 2026 08:00:00 -0400

Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Tue, 07 Jul 2026 08:00:00 -0400

Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Tue, 07 Jul 2026 08:00:00 -0400

Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Tue, 07 Jul 2026 08:00:00 -0400

Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk

Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour

Mon, 29 Jun 2026 07:55:00 -0400

BEIJING--(BUSINESS WIRE)-- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315) today announced that it has received a first-instance civil judgment from the Shanghai Intellectual Property Court. The court ruled that Biocytogen did not infringe the relevant patent rights asserted by the plaintiff, Harbour Antibodies BV ("Harbour"), and ordered the plaintiff to bear the litigation costs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629347368/en/

Court Clears Biocytogen’s RenNano® in Landmark

Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour

Mon, 29 Jun 2026 07:55:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629347368/en/

Court Clears Biocytogen’s RenNano® in Landmark

Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour

Mon, 29 Jun 2026 07:55:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629347368/en/

Court Clears Biocytogen’s RenNano® in Landmark

Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour

Mon, 29 Jun 2026 07:55:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629347368/en/

Court Clears Biocytogen’s RenNano® in Landmark

Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour

Mon, 29 Jun 2026 07:55:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629347368/en/

Court Clears Biocytogen’s RenNano® in Landmark

Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour

Mon, 29 Jun 2026 07:55:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629347368/en/

Court Clears Biocytogen’s RenNano® in Landmark

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Mon, 15 Jun 2026 08:00:00 -0400

BOSTON--(BUSINESS WIRE)-- Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615780515/en/

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity,

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Mon, 15 Jun 2026 08:00:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615780515/en/

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity,

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Mon, 15 Jun 2026 08:00:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615780515/en/

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity,

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Mon, 15 Jun 2026 08:00:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615780515/en/

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity,

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Mon, 15 Jun 2026 08:00:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615780515/en/

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity,

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Mon, 15 Jun 2026 08:00:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615780515/en/

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity,

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Mon, 15 Jun 2026 08:00:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615780515/en/

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity,

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Mon, 15 Jun 2026 08:00:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615780515/en/

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity,

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Mon, 15 Jun 2026 08:00:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615780515/en/

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity,